STAAR Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)
December 17 2019 - 7:00AM
Business Wire
CCRS Plans to Open First Lens-Based Clinic in
Los Angeles County Offering Visian ICL as the Clinic’s Primary
Refractive Solution
CCRS Provides Eye Care and Vision Correction
Solutions
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, today announced it has entered into a
strategic alliance with the California Center for Refractive
Surgery (CCRS), a Los Angeles based eye care group with locations
in Hancock Park and Sherman Oaks.
“Our new multi-clinic alliance with CCRS and its founder Dr.
Paul Lee is representative of the new strategic partnership model
we are now offering to highly-qualified ophthalmic partners in the
U.S., the second largest market for refractive vision correction in
the world,” said Caren Mason, President and CEO of STAAR Surgical.
“Dr. Lee is a leading ophthalmic surgeon who attended our inaugural
U.S. Surgeons Council Summit earlier this year, has subsequently
increased his commitment to use our Visian ICL family of lenses for
vision correction in his clinics and now has plans to open one of
the first lens-based only clinics in the United States in the near
future. We look forward to supporting Dr. Lee’s practice
development through digital marketing, patient education tools and
certified surgeon and staff training relating to the Visian ICL as
we partner to address the growing patient need for vision
correction in the U.S.”
Dr. Lee has performed thousands of various refractive procedures
over an illustrious career spanning more than 20 years. His
distinctions include being a leading Visian ICL (Implantable
Collamer Lens) surgeon, the first U.S. surgeon to be certified in
SMILE and receiving the Alcon Centurion Surgeon Award.
“My goal as a surgeon has always been to give patients freedom
from their glasses for a lifetime and the Visian ICL family of
implantable Collamer lenses can play a key role in doing just
that,” said Dr. Paul Lee, Founder and Medical Director of CCRS.
“The ICL is a quick additive procedure that preserves future
options by leaving the eye in its most natural state. This has
far-reaching implications for patients in terms of visual outcome
and satisfaction, both short term and long term. There is growing
awareness and acceptance of lens-based surgery, such as the Visian
ICL, as surgeons like myself begin to see limitations of cornea
based refractive procedures as the standard of care. The ICL is
removable which potentially gives a patient the option as they age
to replace the ICL lens with a lens that addresses presbyopia
and/or cataracts. Data and experience with the ICL, particularly
overseas where surgeons have utilized the lenses more broadly, is
outstanding and I am currently identifying potential locations in
the greater Pasadena area for a lens-based only clinic where we
will offer the ICL as the primary refractive solution. My staff and
I are excited to offer even more patients the advantages of the
Visian ICL family of lenses, which include no dry-eye syndrome or
weakening of the cornea and excellent vision outcomes.”
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL”, which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
About California Center for Refractive
Surgery (CCRS)
California Center for Refractive Surgery (CCRS) was established
in 2000 with a mission of providing patients with the most advanced
and personalized eye care at an affordable price. Since
establishing CCRS, Dr. Paul C. Lee has dedicated himself to these
causes and stayed at the forefront of eye care and vision
correction surgery. He has been a pioneer who has consistently
implemented the latest technologies in both diagnostics and
treatments to offer safe and effective eye care. CCRS’s other
clinics offer a variety of procedures in addition to the
Implantable Collamer Lens (ICL) such as LASIK and SMILE. CCRS is an
outcome-driven practice with the goal of obtaining excellent
achievable vision for patients, determining and meeting individual
expectations, and providing sincere and caring service. CCRS has
clinic locations in the Hancock Park area of Los Angeles and
Sherman Oaks. For more information, please visit the Company’s
website at www.ccrsclearvision.com.
ATTENTION:
For Physicians: Please reference the Visian ICL Product
Information for a complete listing of indications, warnings, and
precautions.
For Patients: Before considering Visian ICL surgery you should
talk with your eye care professional about Visian ICL surgery,
especially the potential benefits, risks, and complications.
Forward-Looking
Statements
This news release contains forward-looking statements. These
statements include but are not limited to statements regarding the
potential commercial and medical significance of the VISIAN ICL
family of products in the market, and our ability to obtain and
maintain regulatory market approval. Forward-looking statements are
based on our current expectations or beliefs regarding future
events or circumstances, and you should not place undue reliance on
these statements. Such statements involve known and unknown risks,
uncertainties, assumptions and other factors, many of which are out
of STAAR’s control and difficult to forecast that may cause actual
results to differ materially from those that may be described or
implied in the forward-looking statements. STAAR cannot be certain
about the commercial success of the VISIAN ICL family of products
in any market. For a discussion of certain other risks,
uncertainties and other factors affecting the statements contained
in this news release, see STAAR’s Annual Report on Form 10-K for
the year ended December 28, 2018, under the caption “Risk Factors,”
which is on file with the SEC and available in the “Investor
Information” section of STAAR’s website under the heading “SEC
Filings”. Except as required by law, STAAR assumes no, and hereby
disclaims any, obligation to update any of the foregoing or any
other forward-looking statements. STAAR nonetheless reserves the
right to make such updates from time to time by press release,
periodic report or other method of public disclosure without the
need for specific reference to this news release. No such update
shall be deemed to indicate that other statements not addressed by
such update remain correct or create an obligation to provide any
other updates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191217005243/en/
Investors & Media Brian Moore Sr. Director, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2024 to Sep 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2023 to Sep 2024